<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784290</url>
  </required_header>
  <id_info>
    <org_study_id>Taiho132070</org_study_id>
    <nct_id>NCT00784290</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Orantinib, an oral
      tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, platelet-derived
      growth factor receptor, and fibroblast growth factor receptor, in patients with advanced
      hepatocellular carcinoma (HCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As HCC is a highly vascular tumor, a number of antiangiogenic agents have been tested for the
      treatment of HCC. Orantinib is an orally administered, small-molecule, multiple receptor
      tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2
      (VEGFR-2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor
      receptor (FGFR). Phase I studies that have been conducted in Japan for patients with solid
      tumors recommended a dosage of 400 mg bid. As a potent antiangiogenic agent, Orantinib is
      also expected to be effective against HCC. However, because most HCC patients have
      accompanying liver cirrhosis or hepatitis, its safety must be reevaluated in the presence of
      liver function impairment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Step 1(Phase I) Safety</measure>
    <time_frame>During chemotherapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Step 2(Phase II) Response rate(RR)</measure>
    <time_frame>Until progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Step 1(Phase I) Response rate(RR)</measure>
    <time_frame>Until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step 2(Phase II) Safety</measure>
    <time_frame>During chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orantinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orantinib (TSU-68)</intervention_name>
    <description>200 or 400 mg bid day 1ï½žday 28 cycle until progression or unacceptable toxicity develops</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-74

          -  PS 0-2

          -  Patients who did not respond to surgery, RFA, TAE, chemotherapy, or radiotherapy

          -  Chid-Pugh A or B

          -  At least one measurable lesion by RECIST criteria

        Exclusion Criteria:

          -  Large amount of pleural effusion or ascites

          -  Esophageal varices

          -  Simultaneously active double cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masao Omata, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Yamanashi Prefectural Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Inohana Chuo-ku Chiba</city>
        <state>Chiba</state>
        <zip>260-8670</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2008</study_first_posted>
  <last_update_submitted>March 22, 2012</last_update_submitted>
  <last_update_submitted_qc>March 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orantinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

